<!DOCTYPE html>
<html lang='en'><head>
  <meta charset='utf-8'>
<meta name='viewport' content='width=device-width, initial-scale=1'>
<meta name='description' content='Study Location Interventions Start date End date     Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID19 : A Randomized Control Trial Bangkok Thailand Lopinavir and Ritonavir Oseltamivir moderate to severe COVID19, Darunavir and Ritonavir plus oseltamivir, Favipiravir lopinavir /Ritonavir for mod. To severe, Oseltamivir plus Chloroquine in Mild COVID19, Darunavir /ritonavir oseltamivir chloroquine mod-severe, Lopinavir and Ritonavir plus Oseltamivir in mild COVID19, Darunavir /ritonavir favipiravir chloroquine mod-severe March 15, 2020 November 30, 2020   Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic Barcelona Spain Control group with placebo, Pre-exposure prophylaxis of SARS-CoV-2 April 3, 2020 October 30, 2020   The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine) Philadelphia United States Cohort 2 HCQ high dose, Cohort 1 Placebo, Cohort 1 HCQ, Cohort 2 HCQ low dose, Cohort 3 Placebo, Cohort 3 HCQ April 6, 2020 December 1, 2021   Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19.'>
<meta name='theme-color' content='#ffcd00'>

<meta property='og:title' content=' • Covid Papers'>
<meta property='og:description' content='Study Location Interventions Start date End date     Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID19 : A Randomized Control Trial Bangkok Thailand Lopinavir and Ritonavir Oseltamivir moderate to severe COVID19, Darunavir and Ritonavir plus oseltamivir, Favipiravir lopinavir /Ritonavir for mod. To severe, Oseltamivir plus Chloroquine in Mild COVID19, Darunavir /ritonavir oseltamivir chloroquine mod-severe, Lopinavir and Ritonavir plus Oseltamivir in mild COVID19, Darunavir /ritonavir favipiravir chloroquine mod-severe March 15, 2020 November 30, 2020   Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic Barcelona Spain Control group with placebo, Pre-exposure prophylaxis of SARS-CoV-2 April 3, 2020 October 30, 2020   The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine) Philadelphia United States Cohort 2 HCQ high dose, Cohort 1 Placebo, Cohort 1 HCQ, Cohort 2 HCQ low dose, Cohort 3 Placebo, Cohort 3 HCQ April 6, 2020 December 1, 2021   Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19.'>
<meta property='og:url' content='http://covidpapers.github.io/covid19-trials/'>
<meta property='og:site_name' content='Covid Papers'>
<meta property='og:type' content='article'><meta property='article:section' content=''><meta name='twitter:card' content='summary'>

<meta name="generator" content="Hugo 0.68.3" />

  <title> • Covid Papers</title>
  <link rel='canonical' href='http://covidpapers.github.io/covid19-trials/'>
  
  
  <link rel='icon' href='/favicon.ico'>
<link rel='stylesheet' href='/assets/css/main.ab98e12b.css'><link rel='stylesheet' href='/css/custom.css'><style>
:root{--color-accent:#ffcd00;}
</style>

<script type="application/javascript">
var doNotTrack = false;
if (!doNotTrack) {
	window.ga=window.ga||function(){(ga.q=ga.q||[]).push(arguments)};ga.l=+new Date;
	ga('create', 'UA-162547481-1', 'auto');
	
	ga('send', 'pageview');
}
</script>
<script async src='https://www.google-analytics.com/analytics.js'></script>

  

</head>
<body class='page type-page has-sidebar'>

  <div class='site'><div id='sidebar' class='sidebar'>
  <a class='screen-reader-text' href='#main-menu'>Skip to Main Menu</a>

  <div class='container'><section class='widget widget-about sep-after'>
  <header>
    
    <div class='logop'>
      <a href='/'>
        <img src='/logo.jpg'>
      </a>
    </div>
    
    <h2 class='title site-title '>
      <a href='/'>
      Covid Papers
      </a>
    </h2>
    <div class='desc'>
    Curated commentary on COVID papers
    </div>
  </header>

</section>
<section class='widget widget-taxonomy_cloud sep-after'>
  <header>
    <h4 class='title widget-title'>Categories</h4>
  </header>

  <div class='container list-container'>
  <ul class='list taxonomy-cloud'><li>
        <a href='/categories/climate/' style='font-size:1em'>climate</a>
      </li><li>
        <a href='/categories/clinical/' style='font-size:1.6666666666666665em'>clinical</a>
      </li><li>
        <a href='/categories/epidemiology/' style='font-size:1.6666666666666665em'>epidemiology</a>
      </li><li>
        <a href='/categories/immunity/' style='font-size:1em'>immunity</a>
      </li><li>
        <a href='/categories/prevention/' style='font-size:2em'>prevention</a>
      </li><li>
        <a href='/categories/public-health/' style='font-size:1em'>public health</a>
      </li><li>
        <a href='/categories/testing/diagnosis/' style='font-size:1em'>testing/diagnosis</a>
      </li><li>
        <a href='/categories/treatment/' style='font-size:1.3333333333333333em'>treatment</a>
      </li></ul>
</div>


</section>
</div>

  <div class='sidebar-overlay'></div>
</div><div class='main'><nav id='main-menu' class='menu main-menu' aria-label='Main Menu'>
  <div class='container'>
    <a class='screen-reader-text' href='#content'>Skip to Content</a>

<button id='sidebar-toggler' class='sidebar-toggler' aria-controls='sidebar'>
  <span class='screen-reader-text'>Toggle Sidebar</span>
  <span class='open'><svg class='icon' viewbox='0 0 24 24' stroke-linecap='round' stroke-linejoin='round' stroke-width='2' aria-hidden='true'>
  
  <line x1="3" y1="12" x2="21" y2="12" />
  <line x1="3" y1="6" x2="21" y2="6" />
  <line x1="3" y1="18" x2="21" y2="18" />
  
</svg>
</span>
  <span class='close'><svg class='icon' viewbox='0 0 24 24' stroke-linecap='round' stroke-linejoin='round' stroke-width='2' aria-hidden='true'>
  
  <line x1="18" y1="6" x2="6" y2="18" />
  <line x1="6" y1="6" x2="18" y2="18" />
  
</svg>
</span>
</button>
    <ul>
      <li class='item'>
        <a href='https://ko-fi.com/F1F81KK4Q' target='_blank'><img height='36' style='border:0px;height:36px;' src='https://cdn.ko-fi.com/cdn/kofi1.png?v=2' border='0' alt='Buy Me a Coffee at ko-fi.com' /></a>
      </li><li class='item'>
        <a href='/about'>About</a>
      </li><li class='item'>
        <a href='/covid19-cases'>Cases</a>
      </li><li class='item'>
        <a href='/covid19-deaths'>Deaths</a>
      </li><li class='item'>
        <a href='/covid19-testing'>Tests</a>
      </li></ul>
  </div>
</nav><div class='header-widgets'>
        <div class='container'>
    <style>.widget-breadcrumbs li:after{content:'\2f '}</style>
  <section class='widget widget-breadcrumbs sep-after'>
    <nav id='breadcrumbs'>
      <ol><li><a href='/'>Covid Papers</a></li><li><span></span></li></ol>
    </nav>
  </section></div>
      </div>

      <header id='header' class='header site-header'>
        <div class='container sep-after'>
          <div class='header-info'><p class='site-title title'>Covid Papers</p><p class='desc site-desc'>Curated commentary on COVID papers</p>
          </div>
        </div>
      </header>

      <main id='content'>


<article lang='en' class='entry'>
  <header class='header entry-header'>
  <div class='container sep-after'>
    <div class='header-info'>
      <h1 class='title'></h1>            
      <a href="https://twitter.com/PapersCovid?ref_src=twsrc%5Etfw" class="twitter-follow-button" data-show-count="false">Follow @PapersCovid</a><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><br>            
      

    </div>
    <div class='entry-meta'>
  <span class='posted-on'><svg class='icon' viewbox='0 0 24 24' stroke-linecap='round' stroke-linejoin='round' stroke-width='2' aria-hidden='true'>
  
  <rect x="3" y="4" width="18" height="18" rx="2" ry="2"/>
  <line x1="16" y1="2" x2="16" y2="6"/>
  <line x1="8" y1="2" x2="8" y2="6"/>
  <line x1="3" y1="10" x2="21" y2="10"/>
  
</svg>
<span class='screen-reader-text'>Posted on </span>
  <time class='entry-date' datetime='0001-01-01T00:00:00Z'>Monday, January 1, 0001</time>
</span>

  
  
<span class='reading-time'><svg class='icon' viewbox='0 0 24 24' stroke-linecap='round' stroke-linejoin='round' stroke-width='2' aria-hidden='true'>
  
  <circle cx="12" cy="12" r="10"/>
  <polyline points="12 6 12 12 15 15"/>
  
</svg>
31 mins read
</span>


</div>


    <div class="addthis_inline_share_toolbox_dp3y"></div> 
  </div>
</header>
                
  
  
    
  <div class='container entry-content'>  
  <table>
<thead>
<tr>
<th>Study</th>
<th>Location</th>
<th>Interventions</th>
<th>Start date</th>
<th>End date</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04303299">Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID19 : A Randomized Control Trial</a></td>
<td>Bangkok Thailand</td>
<td>Lopinavir and Ritonavir Oseltamivir moderate to severe COVID19, Darunavir and Ritonavir plus oseltamivir, Favipiravir lopinavir /Ritonavir for mod. To severe, Oseltamivir plus Chloroquine in Mild COVID19, Darunavir /ritonavir oseltamivir chloroquine mod-severe, Lopinavir and Ritonavir plus Oseltamivir in mild COVID19, Darunavir /ritonavir favipiravir chloroquine mod-severe</td>
<td>March 15, 2020</td>
<td>November 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04331834">Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic</a></td>
<td>Barcelona Spain</td>
<td>Control group with placebo, Pre-exposure prophylaxis of SARS-CoV-2</td>
<td>April 3, 2020</td>
<td>October 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04329923">The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)</a></td>
<td>Philadelphia United States</td>
<td>Cohort 2 HCQ high dose, Cohort 1 Placebo, Cohort 1 HCQ, Cohort 2 HCQ low dose, Cohort 3 Placebo, Cohort 3 HCQ</td>
<td>April 6, 2020</td>
<td>December 1, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04306497">Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19.</a></td>
<td>Huaian China</td>
<td>Cohort of integrated TCM and western medicine, Cohort of western medicine</td>
<td>March 2, 2020</td>
<td>May 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04285801">Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study</a></td>
<td>Hong Kong Hong Kong</td>
<td>Unknown</td>
<td>February 14, 2020</td>
<td>February 25, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04312997">The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection</a></td>
<td>Houston United States</td>
<td>PUL-042 Inhalation Solution, Sterile normal saline for inhalation</td>
<td>April 2020</td>
<td>October 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04273581">The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19</a></td>
<td>Unknown</td>
<td>Control group, Thalidomide group</td>
<td>February 18, 2020</td>
<td>May 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04324190">DIgital Online SuPport for COVID-19 StrEss</a></td>
<td>Berlin Germany</td>
<td>Online support program, waiting period (WHO recommendation)</td>
<td>March 2020</td>
<td>December 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04323644">Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg)</a></td>
<td>Unknown</td>
<td>Cohort 1</td>
<td>March 31, 2020</td>
<td>September 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04317092">Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</a></td>
<td>Ravenna Italy, Varese Italy, Pesaro Italy, Villafranca Di Verona Italy, Modena Italy, Magenta Italy, Catania Italy, Busto Arsizio Italy, Rimini Italy, Alessandria Italy, Reggio Calabria Italy, Rome Italy, Verona Italy, Cosenza Italy, Naples Italy, Pozzuoli Italy</td>
<td>tocilizumab treatment</td>
<td>March 19, 2020</td>
<td>December 19, 2022</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04319016">Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy</a></td>
<td>Napoli Italy</td>
<td>Unknown</td>
<td>January 1, 2020</td>
<td>May 1, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04287686">Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19</a></td>
<td>Guangzhou China</td>
<td>rhACE2 group</td>
<td>February 2020</td>
<td>April 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04315896">Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)</a></td>
<td>Unknown</td>
<td>treatment, placebo</td>
<td>March 23, 2020</td>
<td>March 22, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04273529">The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia</a></td>
<td>Unknown</td>
<td>Control group, Thalidomide group</td>
<td>February 20, 2020</td>
<td>June 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04327349">Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial</a></td>
<td>Sari Iran, Islamic Republic of</td>
<td>COVID-19 Patients</td>
<td>March 28, 2020</td>
<td>September 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04326114">Effectiveness and Safety of Respiratory Training in the Prevention and Severity of COVID-19</a></td>
<td>Unknown</td>
<td>Inspiratory training, Expiratory training</td>
<td>April 26, 2020</td>
<td>October 12, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04324684">Prognostic Factors Keeping Track for Covid19 Pneumonia</a></td>
<td>Roma Italy</td>
<td>Unknown</td>
<td>March 31, 2020</td>
<td>June 15, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04320511">Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2</a></td>
<td>Royal Oak United States</td>
<td>Patients with SARS-COV 2</td>
<td>April 2020</td>
<td>March 2022</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04279899">The Investigation of the Neonates With or With Risk of COVID-19</a></td>
<td>Shanghai China, Wuhan China</td>
<td>Unknown</td>
<td>February 1, 2020</td>
<td>December 31, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04331886">An Observational Study of Patients With Coronavirus Disease 2019</a></td>
<td>Unknown</td>
<td>Unknown</td>
<td>April 2020</td>
<td>March 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04276896">Immunity and Safety of Covid-19 Synthetic Minigene Vaccine</a></td>
<td>Shenzhen China</td>
<td>pathogen-specific DC and CTLs</td>
<td>March 24, 2020</td>
<td>December 31, 2024</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04325633">Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection</a></td>
<td>Unknown</td>
<td>2: Standard of care, 1: Naproxen</td>
<td>March 27, 2020</td>
<td>June 27, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04270383">Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children</a></td>
<td>Beijing China</td>
<td>Unknown</td>
<td>February 15, 2020</td>
<td>December 31, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04305457">Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19</a></td>
<td>Boston United States</td>
<td>Nitric Oxide inhalation</td>
<td>March 21, 2020</td>
<td>April 1, 2022</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04327180">PREdiction of DIagnosed Covid-19 infecTion in IUC Patients</a></td>
<td>Lille France</td>
<td>Unknown</td>
<td>March 30, 2020</td>
<td>September 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04333472">Piclidenoson for Treatment of COVID-19</a></td>
<td>Petah tikva Israel</td>
<td>Piclidenoson</td>
<td>April 6, 2020</td>
<td>July 6, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04315298">Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19</a></td>
<td>Brooklyn United States, Dallas United States, Everett United States, Denver United States, Newark United States, Aurora United States, Coral Gables United States, Falls Church United States, Orlando United States, Valhalla United States, Elmhurst United States, Detroit United States, Gainesville United States, Bronx United States, Stony Brook United States, Santa Monica United States, Decatur United States, Neptune United States, Teaneck United States, Edison United States, Rochester United States, New Haven United States, Washington United States, Morristown United States, Chicago United States, Boston United States, Hackensack United States, Baltimore United States, Manhasset United States, Philadelphia United States, New York United States, Murray United States, Palo Alto United States, Renton United States, Marietta United States, Sacramento United States, Livingston United States, Ann Arbor United States, Portland United States, Los Angeles United States, Atlanta United States</td>
<td>Sarilumab high dose, Placebo, Sarilumab low dose</td>
<td>March 16, 2020</td>
<td>March 16, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04321993">Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients</a></td>
<td>Unknown</td>
<td>Hydroxychloroquine sulfate, Lopinavir/ritonavir, Sarilumab, Baricitinib</td>
<td>March 2020</td>
<td>July 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04318431">Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children</a></td>
<td>Paris France, Saint-Maur-des-FossÃ©s France, Villejuif France, ChenneviÃ¨res-sur-Marne France, Les Lilas France, Combs-la-Ville France, Nogent-sur-Marne France, Champigny-sur-Marne France, Boulogne France, Maisons-Alfort France, Vincennes France, Montgeron France</td>
<td>Data collection and rhinopharyngeal swab</td>
<td>April 2020</td>
<td>June 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04332081">Hyperbaric Oxygen for COVID-19 Patients</a></td>
<td>Mineola United States</td>
<td>Hyperbaric oxygen therapy (HBOT)</td>
<td>April 2020</td>
<td>July 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04322487">Simple, Safe, Same: Lung Ultrasound for COVID-19</a></td>
<td>Pavia Italy, Brescia Italy, Roma Italy, Lucca Italy, Trento Italy, Voghera Italy, Lodi Italy</td>
<td>Unknown</td>
<td>April 1, 2020</td>
<td>January 15, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04330638">Treatment of COVID-19 Patients With Anti-interleukin Drugs</a></td>
<td>Gent Belgium, Edegem Belgium, Jette Belgium, LiÃ¨ge Belgium, Brugge Belgium, Genk Belgium, Brussels Belgium</td>
<td>Tocilizumab, Anakinra, Anakinra + Siltuximab, Siltuximab, Usual Care, Anakinra + Tocilizumab</td>
<td>April 2020</td>
<td>December 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04304313">A Pilot Study of Sildenafil in COVID-19</a></td>
<td>Wuhan China</td>
<td>Sildenafil citrate tablets</td>
<td>February 9, 2020</td>
<td>November 9, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04322513">Biomarkers for Identification of SARS-COV-2 Infection</a></td>
<td>Catanzaro Italy</td>
<td>Covid-19 positive patients, Covid-19 negative patients</td>
<td>March 24, 2020</td>
<td>August 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04333420">OPEN LABEL, RANDOMIZED PHASE II/III STUDY OF IFX-1 IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA</a></td>
<td>Amsterdam Netherlands</td>
<td>Arm A, Arm B</td>
<td>March 31, 2020</td>
<td>December 31, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04330521">Impact of the Coronavirus (COVID-19) on Patients With Cancer</a></td>
<td>Unknown</td>
<td>Unknown</td>
<td>April 2020</td>
<td>May 2022</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04333953">COVID-19 in Patients With HIV</a></td>
<td>Columbia United States</td>
<td>Unknown</td>
<td>April 1, 2020</td>
<td>October 1, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04307693">Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)</a></td>
<td>Seoul Korea, Republic of</td>
<td>Lopinavir/ritonavir, Hydroxychloroquine</td>
<td>March 11, 2020</td>
<td>May 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04278963">Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19</a></td>
<td>Wuhan China, Jingzhou China, Xiangyang China</td>
<td>Yin Hu Qing Wen Decoction Group, Integrated Chinese and Western Medicine group, Yinhu Qingwen Decoction low-dose group</td>
<td>February 27, 2020</td>
<td>January 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04319315">Social Media Effect on Knowledge Dissemination During COVID-19 Virus Outbreak</a></td>
<td>Assiut Egypt</td>
<td>Unknown</td>
<td>March 11, 2020</td>
<td>March 16, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04319445">Mindfulness During COVID-19</a></td>
<td>Unknown</td>
<td>Migraine Patients/Providers/Faculty/Staff/Other</td>
<td>March 2020</td>
<td>December 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04316299">Acute Kidney Injury in Patients Hospitalized With COVID-19</a></td>
<td>Wuhan China</td>
<td>Unknown</td>
<td>February 26, 2020</td>
<td>March 8, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04315987">NestCellÂ® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia</a></td>
<td>SÃ£o Paulo Brazil</td>
<td>NestCellÂ® - phase 1, NestCellÂ® - phase 2</td>
<td>April 2020</td>
<td>June 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04320615">A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</a></td>
<td>Unknown</td>
<td>Tocilizumab (TCZ) Arm, Placebo Arm</td>
<td>April 3, 2020</td>
<td>September 30, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04331366">Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19</a></td>
<td>Atlanta United States</td>
<td>Treatment with GO2 PEEP MOUTHPIECE</td>
<td>April 2020</td>
<td>April 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04280588">Fingolimod in COVID-19</a></td>
<td>Fuzhou China</td>
<td>Treatment group</td>
<td>February 22, 2020</td>
<td>July 1, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04324528">Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation</a></td>
<td>Freiburg Germany</td>
<td>vv-ECMO + cytokine adsorption, control-arm: vv-ECMO (no cytokine adsorption)</td>
<td>March 27, 2020</td>
<td>November 26, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04304690">Sars-CoV2 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic</a></td>
<td>Paris France</td>
<td>caregiver</td>
<td>March 16, 2020</td>
<td>October 16, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04325919">Coronavirus Disease 2019 (COVID-19) Study of Hospitalized Patients in Hong Kong</a></td>
<td>Sha Tin Hong Kong</td>
<td>Unknown</td>
<td>February 24, 2020</td>
<td>June 17, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04305106">Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT</a></td>
<td>Jinan China</td>
<td>Bevacizumab Group</td>
<td>March 17, 2020</td>
<td>July 31, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04334005">Vitamin D on Prevention and Treatment of COVID-19</a></td>
<td>Granada Spain</td>
<td>Intervention group, Usual care</td>
<td>April 10, 2020</td>
<td>June 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04292899">Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe Coronavirus Disease (COVID-19)</a></td>
<td>Barcelona Spain, Harbor City United States, Dallas United States, Daegu Korea, Republic of, Everett United States, Jamaica United States, Temple United States, Tacoma United States, Newark United States, Falls Church United States, Anaheim United States, Munich Germany, GenÃ¨ve 14 Switzerland, Newport Beach United States, Spokane United States, Parma Italy, Oakland United States, Houston United States, Kaohsiung Taiwan, Seoul Korea, Republic of, London United Kingdom, Downey United States, Singapore Singapore, Taichung Taiwan, San Francisco United States, New Brunswick United States, Seattle United States, Padova PD Italy, Lugano Switzerland, Bronx United States, Santa Monica United States, Santa Rosa United States, Ontario United States, Richmond United States, Hillsboro United States, San Diego United States, Lebanon United States, Pavia Italy, Manchester United Kingdom, Rochester United States, Fontana United States, Panorama City United States, New Haven United States, Manhasset United States, Chicago United States, Boston United States, ZÃ¼rich Switzerland, Lagrangeville United States, Minneapolis United States, New York United States, Philadelphia United States, Taipei City Taiwan, Fort Worth United States, Stanford United States, Cremona Italy, Madrid Spain, Hillsborough United States, Providence United States, Cleveland United States, Brescia Italy, Hong Kong Hong Kong, Portland United States, Los Angeles United States, Hackensack United States, Moreno Valley United States</td>
<td>Remdesivir (RDV), 5 Days, Remdesivir, 10 Days</td>
<td>March 6, 2020</td>
<td>May 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04296643">Medical Masks vs N95 Respirators for COVID-19</a></td>
<td>Unknown</td>
<td>Medical Mask, N95 respirator</td>
<td>April 1, 2020</td>
<td>January 1, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04329572">Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19</a></td>
<td>Unknown</td>
<td>HCQ + AZT</td>
<td>April 3, 2020</td>
<td>June 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04334044">Treatment of SARS Caused by COVID-19 With Ruxolitinib</a></td>
<td>Huixquilucan Mexico</td>
<td>Ruxolitinib</td>
<td>April 1, 2020</td>
<td>June 1, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04292730">Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</a></td>
<td>Barcelona Spain, Harbor City United States, Dallas United States, Daegu Korea, Republic of, Kiel Germany, Everett United States, Jamaica United States, Temple United States, Tacoma United States, Newark United States, Falls Church United States, Anaheim United States, Munich Germany, GenÃ¨ve 14 Switzerland, Newport Beach United States, Spokane United States, Parma Italy, Houston United States, Kaohsiung Taiwan, Seoul Korea, Republic of, London United Kingdom, Downey United States, Singapore Singapore, Taichung Taiwan, San Francisco United States, New Brunswick United States, Seattle United States, Padova PD Italy, Lugano Switzerland, Bronx United States, Santa Monica United States, Santa Rosa United States, Ontario United States, Richmond United States, Hillsboro United States, Milano Italy, San Diego United States, Lebanon United States, Pavia Italy, Manchester United Kingdom, Rochester United States, Fontana United States, Panorama City United States, New Haven United States, Manhasset United States, Chicago United States, Boston United States, ZÃ¼rich Switzerland, Lagrangeville United States, Minneapolis United States, New York United States, Philadelphia United States, Bizkaia Spain, Taipei City Taiwan, Fort Worth United States, Stanford United States, Cremona Italy, Madrid Spain, Hamburg Germany, Hillsborough United States, Providence United States, Cleveland United States, Brescia Italy, Guangzhou China, Iowa City United States, Portland United States, Hong Kong Hong Kong, Los Angeles United States, DÃ¼sseldorf Germany, Hackensack United States, Moreno Valley United States</td>
<td>Continued SOC Therapy, Remdesivir (RDV), 5 Days, Remdesivir, 10 Days</td>
<td>March 15, 2020</td>
<td>May 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04332107">Azithromycin for COVID-19 Treatment in Outpatients Nationwide</a></td>
<td>San Francisco United States</td>
<td>Placebo, Azithromycin</td>
<td>April 1, 2020</td>
<td>July 30, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04323631">Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death</a></td>
<td>Unknown</td>
<td>The control group, The intervention group</td>
<td>March 2020</td>
<td>December 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04331470">Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19</a></td>
<td>Unknown</td>
<td>Standard care, Levamisole Pill + Budesonide+Formoterol inhaler+Standard care</td>
<td>March 31, 2020</td>
<td>May 20, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04333628">Chloroquine for Mild Symptomatic and Asymptomatic COVID-19</a></td>
<td>Unknown</td>
<td>Standard of care, Regular dose chloroquine, low dose chloroquine</td>
<td>April 2020</td>
<td>December 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04322188">An Observational Case-control Study of the Use of Siltuximab in ARDS Patients Diagnosed With COVID-19 Infection</a></td>
<td>Bergamo Italy</td>
<td>Cohort B, Cohort A</td>
<td>March 19, 2020</td>
<td>May 19, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04308317">Tetrandrine Tablets Used in the Treatment of COVID-19</a></td>
<td>Jinhua China</td>
<td>Tetrandrine Cohort</td>
<td>March 5, 2020</td>
<td>May 1, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04321096">The Impact of Camostat Mesilate on COVID-19 Infection</a></td>
<td>Aalborg Denmark, Aarhus N Denmark, Odense Denmark</td>
<td>Placebo, Camostat Mesilate</td>
<td>March 31, 2020</td>
<td>May 1, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04328441">Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine</a></td>
<td>Rotterdam Netherlands, Utrecht Netherlands, Alkmaar Netherlands, Nijmegen Netherlands, Den Haag Netherlands, Den Bosch Netherlands, Leiden Netherlands</td>
<td>BCG vaccine, Placebo</td>
<td>March 25, 2020</td>
<td>December 25, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04326790">The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention</a></td>
<td>Unknown</td>
<td>Control, Intervention</td>
<td>April 6, 2020</td>
<td>September 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04286503">The Clinical Study of Carrimycin on Treatment Patients With COVID-19</a></td>
<td>Unknown</td>
<td>Carrimycin, lopinavir/ritonavir or Arbidol or chloroquine phosphate</td>
<td>February 23, 2020</td>
<td>February 28, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04324736">&ldquo;Coronavirus SARS-CoV2 and Diabetes Outcomes&rdquo;</a></td>
<td>Unknown</td>
<td>Patient</td>
<td>March 30, 2020</td>
<td>May 8, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04288102">Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)</a></td>
<td>Wuhan China</td>
<td>Mesenchymal Stem Cells (MSCs), Placebo</td>
<td>March 5, 2020</td>
<td>December 31, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04326387">Evaluation of Novel Diagnostic Tests for 2019-nCOV</a></td>
<td>Unknown</td>
<td>Research Participants (Patients)</td>
<td>April 8, 2020</td>
<td>October 7, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04329533">Effects of Using Mobile App on Perceived Stress During Coronavirus (&ldquo;COVID 19&rdquo;) Pandemic</a></td>
<td>Unknown</td>
<td>Intervention Group - access to meditation app</td>
<td>April 1, 2020</td>
<td>July 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04325646">Sero-epidemiological Study of the SARS-CoV-2 Virus in France: Constitution of a Collection of Human Biological Samples</a></td>
<td>Limoges France, Paris France, Amiens France, Tours France, Saint-Ã‰tienne France, Tourcoing France, Lyon France, Rennes France, Poitiers France, Nancy France, OrlÃ©ans France, Dijon France</td>
<td>CORSER-2c, CORSER-2b, CORSER-2a, CORSER-1</td>
<td>March 13, 2020</td>
<td>February 28, 2023</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04311177">Losartan for Patients With COVID-19 Not Requiring Hospitalization</a></td>
<td>Minneapolis United States</td>
<td>Placebo, Losartan</td>
<td>April 2, 2020</td>
<td>April 1, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04299152">Stem Cell Educator Therapy Treat the Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2</a></td>
<td>Unknown</td>
<td>Stem Cell Educator therapy treat patients with SARS-CoV-2</td>
<td>April 10, 2020</td>
<td>November 10, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04332913">Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia</a></td>
<td>Unknown</td>
<td>Unknown</td>
<td>April 1, 2020</td>
<td>March 31, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04310865">Yinhu Qingwen Granula for the Treatment of Severe CoVID-19</a></td>
<td>Wuhan China</td>
<td>Yinhu Qingwen Granula Low-dose Group, Yinhu Qingwen Granula Group</td>
<td>March 20, 2020</td>
<td>June 30, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04321265">Outcomes and Prognostic Factors in COVID-19</a></td>
<td>Duesseldorf Germany</td>
<td>Unknown</td>
<td>March 19, 2020</td>
<td>December 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04312100">Sequential Oxygen Therapy Strategy for Patients With COVID-19</a></td>
<td>Zhengzhou China</td>
<td>Moderate/Severe cases with nasal high flow oxygen inhalation, Moderate/Severe cases with non-invasive ventilation, Mild cases with conventional oxygen therapy</td>
<td>February 1, 2020</td>
<td>February 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04321174">COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir</a></td>
<td>Toronto Canada</td>
<td>Lopinavir/ritonavir</td>
<td>March 30, 2020</td>
<td>March 31, 2022</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04325672">Convalescent Plasma to Limit Coronavirus Associated Complications</a></td>
<td>Rochester United States</td>
<td>Convalescent Plasma Group</td>
<td>April 1, 2020</td>
<td>December 31, 2022</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04321928">Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary</a></td>
<td>Unknown</td>
<td>Group B, Group A</td>
<td>April 1, 2020</td>
<td>August 21, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03808922">Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study</a></td>
<td>Brisbane Australia, Gangnam-gu Korea, Republic of, Seocho-gu Korea, Republic of, Omaha United States, Aurora United States, Pittsburgh United States, Houston United States, Cincinnati United States, Nashville United States, Zhongzheng Dist. Taiwan, Richmond United States, Sydney Australia, Songpa-gu Korea, Republic of, Seongnam-si Korea, Republic of, Maywood United States, Chicago United States, Boston United States, Philadelphia United States, Milwaukee United States, Fort Worth United States, Fairway United States, Melbourne Australia, Duarte United States, Portland United States, Durham United States, Saint Louis United States, Los Angeles United States, Jongno-gu Korea, Republic of, Seattle United States</td>
<td>DAS181, Placebo, DAS181 OL, DAS181 COVID-19</td>
<td>May 23, 2019</td>
<td>December 28, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04327804">A Longitudinal Study of SARS-CoV-2 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research</a></td>
<td>Seattle United States</td>
<td>Even numbered birth year, Odd numbered birth year</td>
<td>March 25, 2020</td>
<td>April 10, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04273321">Efficacy and Safety of Corticosteroids in COVID-19</a></td>
<td>Yichang China, Wuhan China, Beijing China, Xiangyang China</td>
<td>MP group</td>
<td>February 14, 2020</td>
<td>May 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04292964">Prognostic Factors of Patients With COVID-19</a></td>
<td>Chongqing China</td>
<td>Unknown</td>
<td>March 1, 2020</td>
<td>March 13, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04285190">The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19</a></td>
<td>Unknown</td>
<td>The T89 treatment group</td>
<td>February 26, 2020</td>
<td>September 15, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04322565">Colchicine Efficacy in COVID-19 Pneumonia</a></td>
<td>Unknown</td>
<td>Colchicine, Standard of care</td>
<td>April 1, 2020</td>
<td>June 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04273763">Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)</a></td>
<td>Wenzhou China</td>
<td>Group B, Group A</td>
<td>February 16, 2020</td>
<td>April 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04306055">Blood Donor Recruitment During Epidemic of COVID-19</a></td>
<td>Unknown</td>
<td>Questionnaire with precaution information, Questionnaire without precaution information</td>
<td>March 12, 2020</td>
<td>April 9, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04316377">Norwegian Coronavirus Disease 2019 Study</a></td>
<td>LÃ¸renskog Norway</td>
<td>Treatment</td>
<td>March 25, 2020</td>
<td>March 3, 2025</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04333914">Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection</a></td>
<td>Lyon France</td>
<td>Chloroquine analog (GNS651), Anti-PD-1 (nivolumab), Standard of care, Anti-IL-6 (tocilizumab)</td>
<td>April 2020</td>
<td>August 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04259892">Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection</a></td>
<td>Paris France</td>
<td>Unknown</td>
<td>February 4, 2020</td>
<td>February 4, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04324047">Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients</a></td>
<td>Paris France, Le Kremlin-BicÃªtre France</td>
<td>Unknown</td>
<td>March 27, 2020</td>
<td>December 31, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04307459">Acute Respiratory Failure and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Real Life</a></td>
<td>Milan Italy</td>
<td>Coronavirus Infection</td>
<td>March 19, 2020</td>
<td>December 31, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04333654">Hydroxychloroquine in Outpatient Adults With COVID-19</a></td>
<td>Boston United States</td>
<td>Placebo, Hydroxychloroquine</td>
<td>March 31, 2020</td>
<td>May 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04327401">COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III</a></td>
<td>Salvador Brazil, SÃ£o Paulo Brazil, Blumenau Brazil, Votuporanga Brazil, Londrina Brazil, Barretos Brazil, PoÃ§os De Caldas Brazil, BrasÃ­lia Brazil, Porto Alegre Brazil, Colatina Brazil, Belo Horizonte Brazil, Natal Brazil, CriciÃºma Brazil</td>
<td>Intervention group</td>
<td>April 1, 2020</td>
<td>August 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04320472">Acute Encephalopathy in Critically Ill Patients With SARS-Cov-2 Infection</a></td>
<td>Le Chesnay France</td>
<td>Follow up</td>
<td>March 23, 2020</td>
<td>December 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04280705">Adaptive COVID-19 Treatment Trial (ACTT)</a></td>
<td>La Jolla United States, Omaha United States, Tokyo Japan, Denver United States, Tacoma United States, Spokane United States, Bethesda United States, Houston United States, Orange United States, Seoul Korea, Republic of, Nashville United States, Singapore Singapore, San Francisco United States, Bronx United States, Decatur United States, San Diego United States, Kirkland United States, Rochester United States, Chicago United States, Boston United States, Fort Sam Houston United States, Baltimore United States, San Antonio United States, Silver Spring United States, Minneapolis United States, New York United States, Philadelphia United States, Palo Alto United States, Galveston United States, Portsmouth United States, Bundang-gu Seongnam-si Korea, Republic of, Annapolis United States, Sacramento United States, Birmingham United States, Durham United States, Saint Louis United States, Los Angeles United States, Seattle United States</td>
<td>Remdesivir, Placebo</td>
<td>February 21, 2020</td>
<td>April 1, 2023</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04279795">Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations</a></td>
<td>Guangzhou China</td>
<td>Unknown</td>
<td>January 20, 2020</td>
<td>February 28, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04315948">Trial of Treatments for COVID-19 in Hospitalized Adults</a></td>
<td>Paris France, Nantes France, Lille France</td>
<td>Lopinavir/ritonavir, Hydroxychloroquine, Remdesivir, Lopinavir/ritonavir plus Interferon ÃŸ-1a, Standard of care</td>
<td>March 22, 2020</td>
<td>March 2023</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04319211">Effects of Social Isolation From Coronavirus; on Physical Activity, Quality of Life and Stress</a></td>
<td>Istanbul Turkey</td>
<td>People who isolate at home with the danger of coronavirus</td>
<td>March 25, 2020</td>
<td>July 20, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04302688">Accurate Classification System for Patients With COVID-19 Pneumonitis</a></td>
<td>Wuhan China</td>
<td>validating colort, modeling cohort</td>
<td>December 10, 2019</td>
<td>March 4, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04292340">Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19</a></td>
<td>Shanghai China</td>
<td>Unknown</td>
<td>February 1, 2020</td>
<td>December 31, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04325867">Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19</a></td>
<td>Bucharest Romania, Iasi Romania</td>
<td>All patients with known cardiovascular disease</td>
<td>March 31, 2020</td>
<td>October 1, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04245631">Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV</a></td>
<td>Beijing China</td>
<td>RAA assay for 2019-nCoV</td>
<td>January 1, 2020</td>
<td>December 31, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04312009">Losartan for Patients With COVID-19 Requiring Hospitalization</a></td>
<td>Minneapolis United States</td>
<td>Placebo, Losartan</td>
<td>April 2, 2020</td>
<td>April 1, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04316949">Predictors of Respiratory Failure in SARS-Cov-2 Infection</a></td>
<td>Bologna Italy</td>
<td>Unknown</td>
<td>March 20, 2020</td>
<td>May 31, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04322344">Escin in Patients With Covid-19 Infection</a></td>
<td>Catanzaro Italy</td>
<td>parenteral escin group, oral escin group, control group</td>
<td>March 23, 2020</td>
<td>August 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04325906">Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS</a></td>
<td>Chicago United States, Wauwatosa United States</td>
<td>HFNC plus prone positioning, high flow nasal cannula only</td>
<td>April 6, 2020</td>
<td>June 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04326452">Treating COVID-19 With a Bidirectional Oxygenation Valve</a></td>
<td>Tucson United States, Atlanta United States, Stanford United States</td>
<td>Enrolled Subjects</td>
<td>March 27, 2020</td>
<td>June 1, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04331613">Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS</a></td>
<td>Beijing China</td>
<td>CAStem</td>
<td>January 27, 2020</td>
<td>December 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04331054">Protective Role of Inhaled Steroids for Covid-19 Infection</a></td>
<td>Paris France</td>
<td>2: Usual practice + SYMBICORT RAPIHALER, 1: Usual practice</td>
<td>April 2020</td>
<td>July 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04322123">Safety and Efficacy of Hydroxychloroquine Associated With Azythromycin in SARS-Cov-2 Virus</a></td>
<td>Salvador Brazil, SÃ£o Paulo Brazil, VitÃ³ria Da Conquista Brazil, Brasilia Brazil, Porto Alegre Brazil, Caxias do Sul Brazil, Colatina Brazil, RibeirÃ£o Preto Brazil, Nova Lima Brazil, Rio De Janeiro Brazil, SÃ£o JoÃ£o Del Rei Brazil, Barretos Brazil, SÃ£o JosÃ© do Rio Preto Brazil, BrasÃ­lia Brazil, Criciuma Brazil, Londrina Brazil, Feira De Santana Brazil, FlorianÃ³polis Brazil, Joinville Brazil</td>
<td>Hydroxychloroquine + azythromycin, Hydroxychloroquine</td>
<td>April 6, 2020</td>
<td>August 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04319172">Multicentric Study of Coronavirus Disease 2019 (COVID-2019) in Solid Organ Transplant Recipients</a></td>
<td>Unknown</td>
<td>Unknown</td>
<td>March 2020</td>
<td>April 2022</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04275414">Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia</a></td>
<td>Wuhan China, Jinan China, Gravedona Italy</td>
<td>bevacizumab plus regular therapy</td>
<td>February 15, 2020</td>
<td>May 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04268537">Immunoregulatory Therapy for 2019-nCoV</a></td>
<td>Unknown</td>
<td>thymosin group, PD-1 group, control group</td>
<td>February 10, 2020</td>
<td>October 31, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04323592">Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome</a></td>
<td>Trieste Italy</td>
<td>Methylprednisolone treated consecutive cases, Controls (non-methylprednisolone treated subjects)</td>
<td>March 23, 2020</td>
<td>May 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04251767">Washed Microbiota Transplantation for Patients With 2019-nCoV Infection</a></td>
<td>Nanjing China</td>
<td>Control group, Observational group</td>
<td>February 5, 2020</td>
<td>April 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04320238">Experimental Trial of rhIFNÎ± Nasal Drops to Prevent 2019-nCOV in Medical Staff</a></td>
<td>Shiyan China</td>
<td>low-risk group, high-risk group</td>
<td>January 21, 2020</td>
<td>June 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04290871">Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.</a></td>
<td>Unknown</td>
<td>Control Group, Treatment Group</td>
<td>March 23, 2020</td>
<td>March 1, 2022</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04321278">Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</a></td>
<td>SÃ£o Paulo Brazil, Blumenau Brazil, Votuporanga Brazil, Londrina Brazil, Barretos Brazil, PoÃ§os De Caldas Brazil, BrasÃ­lia Brazil, Porto Alegre Brazil, Colatina Brazil, Belo Horizonte Brazil, Natal Brazil, CriciÃºma Brazil</td>
<td>Hydroxychloroquine + azithromycin, Hydroxychloroquine</td>
<td>March 28, 2020</td>
<td>August 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04327388">Sarilumab COVID-19</a></td>
<td>Bordeaux Cedex France</td>
<td>Sarilumab Dose 1, Placebo, Sarilumab Dose 2</td>
<td>March 28, 2020</td>
<td>June 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04306705">Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19</a></td>
<td>Wuhan China</td>
<td>Continuous Renal Replacement Therapy, Tocilizumab, Standard care</td>
<td>February 20, 2020</td>
<td>June 20, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04272710">Prognositc Factors in COVID-19 Patients Complicated With Hypertension</a></td>
<td>Chongqing China</td>
<td>Unknown</td>
<td>January 25, 2020</td>
<td>April 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04329195">ACE Inhibitors or ARBs Discontinuation in Context of SARS-CoV-2 Pandemia</a></td>
<td>Unknown</td>
<td>1: discontinuation of RAS blocker therapy, 2: continuation of RAS blocker therapy</td>
<td>March 2020</td>
<td>May 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04332666">Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial</a></td>
<td>Unknown</td>
<td>Placebo, Study drug</td>
<td>March 31, 2020</td>
<td>June 15, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04293692">Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus</a></td>
<td>Wuhan China</td>
<td>Control group, UC-MSCs treatment group</td>
<td>February 24, 2020</td>
<td>February 25, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04321616">The Efficacy of Different Anti-viral Drugs in (Severe Acute Respiratory Syndrome-Corona Virus-2) SARS-CoV-2</a></td>
<td>Unknown</td>
<td>Remdesivir, Control group - SoC, Hydroxychloroquine</td>
<td>March 26, 2020</td>
<td>November 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04323839">PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY)</a></td>
<td>San Francisco United States</td>
<td>Pregnant Women, Post-partum women</td>
<td>March 20, 2020</td>
<td>March 31, 2024</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04264858">Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients</a></td>
<td>Wuhan China</td>
<td>Control group, Treatment group</td>
<td>March 17, 2020</td>
<td>May 31, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04251871">Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection</a></td>
<td>Beijing China</td>
<td>Conventional medicines, Conventional medicines and TCMs granules</td>
<td>January 22, 2020</td>
<td>January 22, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04252118">Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus</a></td>
<td>Beijing China</td>
<td>MSCs Treatment Group</td>
<td>January 27, 2020</td>
<td>December 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04284046">CT Scores Predict Mortality in 2019-nCoV Pneumonia</a></td>
<td>Wuhan China</td>
<td>Low CTscore, High CT score</td>
<td>January 31, 2020</td>
<td>February 18, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04324021">Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.</a></td>
<td>Roma Italy, Milano Italy, Brescia Italy, Parma Italy</td>
<td>Emapalumab, Anakinra</td>
<td>March 2020</td>
<td>September 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04306393">Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19</a></td>
<td>Boston United States</td>
<td>Treatment Group</td>
<td>March 21, 2020</td>
<td>March 21, 2022</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04333368">Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS</a></td>
<td>Paris France</td>
<td>NaCl, MSC</td>
<td>April 1, 2020</td>
<td>May 31, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04252664">Mild/Moderate 2019-nCoV Remdesivir RCT</a></td>
<td>Wu Han China</td>
<td>Remdesivir group, Control group</td>
<td>February 12, 2020</td>
<td>April 27, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04326400">Active Monitoring And Determinants of Incidence Infection of COVDI-19</a></td>
<td>Madrid Spain</td>
<td>Unknown</td>
<td>March 23, 2020</td>
<td>September 20, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04323345">Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus</a></td>
<td>Cairo Egypt</td>
<td>Natural Honey Group, Standard Care</td>
<td>March 25, 2020</td>
<td>May 10, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04279782">Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection</a></td>
<td>Guangzhou China</td>
<td>Exclusion group, Confirmed group</td>
<td>January 20, 2020</td>
<td>February 28, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04321369">Impact of Swab Site and Sample Collector on Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals</a></td>
<td>Seattle United States</td>
<td>Unknown</td>
<td>March 9, 2020</td>
<td>March 23, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04320953">Non-contact Endoscopy at Covid-19 Outbreak</a></td>
<td>Shanghai China</td>
<td>Non-contact MCE examination</td>
<td>March 16, 2020</td>
<td>March 16, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04330599">Longitudinal Population-based Observational Study of Coronavirus Disease in the UK Population</a></td>
<td>Unknown</td>
<td>Unknown</td>
<td>April 2, 2020</td>
<td>April 1, 2025</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04269525">Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia</a></td>
<td>Wuhan China</td>
<td>pneumonia</td>
<td>February 6, 2020</td>
<td>September 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04325893">Hydroxychloroquine Versus Placebo in Patients Presenting COVID-19 Infection and at Risk of Secondary Complication: a Prospective, Multicentre, Randomised, Double-blind Study</a></td>
<td>Unknown</td>
<td>Placebo, Hydroxychloroquine</td>
<td>April 2020</td>
<td>September 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04261426">The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia</a></td>
<td>Unknown</td>
<td>Standard care, IVIG therapy+ standard care</td>
<td>February 10, 2020</td>
<td>June 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04327479">Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection</a></td>
<td>Essen Germany</td>
<td>Unknown</td>
<td>March 26, 2020</td>
<td>March 25, 2026</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04279197">Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu</a></td>
<td>Shanghai China</td>
<td>Basic Treatment+Placebo, Basic Treatment+Fuzheng Huayu Tablet</td>
<td>February 15, 2020</td>
<td>December 2022</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04254874">A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia</a></td>
<td>Wuhan China</td>
<td>Abidol hydrochloride, Abidol Hydrochloride combined with Interferon atomization</td>
<td>February 1, 2020</td>
<td>July 1, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04332042">TOFAcitinib in SARS-CoV2 Pneumonia</a></td>
<td>Ancona Italy</td>
<td>tofacitinib</td>
<td>April 10, 2020</td>
<td>July 10, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04261270">A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia</a></td>
<td>Wuhan China</td>
<td>Ritonavir+Oseltamivir, Oseltamivir, ASC09F+Oseltamivir</td>
<td>February 1, 2020</td>
<td>July 1, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04255017">A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia</a></td>
<td>Wuhan China</td>
<td>Oseltamivir was added on the basis of group I., Abidol hydrochloride was added on the basis of group I., Lopinavir/ritonavir was added on the basis of group I.</td>
<td>February 1, 2020</td>
<td>July 1, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04263402">The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia</a></td>
<td>Wuhan China</td>
<td>Methylprednisolone(&lt;40mg/d), Methylprednisolone(40~80mg/d)</td>
<td>February 1, 2020</td>
<td>July 1, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04326426">COVIDL1: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection</a></td>
<td>Unknown</td>
<td>Placebo, Tradipitant</td>
<td>April 1, 2020</td>
<td>August 31, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04328480">The ECLA PHRI COLCOVID Trial</a></td>
<td>Unknown</td>
<td>Local standard of care plus colchicine, Local standard of care</td>
<td>March 2020</td>
<td>June 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04274322">Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool</a></td>
<td>Unknown</td>
<td>Cohort 2, Cohort 1</td>
<td>February 2020</td>
<td>July 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04324073">Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI</a></td>
<td>Paris France, Le Kremlin-BicÃªtre France</td>
<td>SARILUMAB</td>
<td>March 27, 2020</td>
<td>December 31, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04290780">Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus</a></td>
<td>Lyon France</td>
<td>Unknown</td>
<td>March 9, 2020</td>
<td>October 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04328467">Pre-exposure Prophylaxis for SARS-Coronavirus-2</a></td>
<td>Minneapolis United States</td>
<td>Control Group, Intervention Once Weekly, Intervention Twice Weekly</td>
<td>April 1, 2020</td>
<td>August 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04330300">Coronavirus ACEi/ARB Investigation</a></td>
<td>Galway Ireland</td>
<td>Continue ACEi/ARB antihypertensive, Alternative anti-hypertensive medication</td>
<td>March 30, 2020</td>
<td>March 1, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04331808">Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Tocilizumab Trial - CORIMUNO-19 - TOCI (CORIMUNO-TOCI)</a></td>
<td>Unknown</td>
<td>TOCILIZUMAB</td>
<td>March 31, 2020</td>
<td>December 31, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04322773">Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure</a></td>
<td>Copenhagen Denmark</td>
<td>Standard care, Roactemra iv, Roactemra sc, Kevzara sc</td>
<td>April 4, 2020</td>
<td>June 1, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04295551">Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)</a></td>
<td>Unknown</td>
<td>Experimental group of ordinary COVID-19, Control group of ordinary COVID-19, Experimental group of severe COVID-19</td>
<td>March 14, 2020</td>
<td>April 14, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04333251">Study Testing Convalescent Plasma vs Best Supportive Care</a></td>
<td>Unknown</td>
<td>convalescent plasma, best supportive care</td>
<td>April 1, 2020</td>
<td>December 31, 2022</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04255940">2019-nCoV Outbreak and Cardiovascular Diseases</a></td>
<td>Jinan China, Heze China, Binzhou China, Zibo China, Qihe China, Jining China, Weihai China, Qingdao China</td>
<td>Unknown</td>
<td>January 20, 2020</td>
<td>April 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04283461">Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection</a></td>
<td>Bethesda United States, Seattle United States, Decatur United States</td>
<td>Arm 1, Arm 3, Arm 2</td>
<td>March 3, 2020</td>
<td>June 1, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04323527">Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2</a></td>
<td>Manaus Brazil</td>
<td>High Dose Chloroquine Diphosphate (10 days), Low Dose Chloroquine Diphosphate (5 days)</td>
<td>March 23, 2020</td>
<td>August 31, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04322279">Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection (CoV-CONTACT-SERO)</a></td>
<td>Paris France</td>
<td>Unknown</td>
<td>March 9, 2020</td>
<td>May 1, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04314817">Adverse Events Related to Treatments Used Against Coronavirus Disease 2019</a></td>
<td>Paris France</td>
<td>Patients treated for Covid-19</td>
<td>March 17, 2020</td>
<td>January 1, 2023</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04308187">Influence of the COvid-19 Epidemic on STRESS</a></td>
<td>Clermont-Ferrand France</td>
<td>Unknown</td>
<td>March 11, 2020</td>
<td>March 2022</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04311398">Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System</a></td>
<td>Shanghai China</td>
<td>Respiratory infection group</td>
<td>March 14, 2020</td>
<td>December 1, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04264533">Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia</a></td>
<td>Wuhan China</td>
<td>VC, Sterile water for injection</td>
<td>February 14, 2020</td>
<td>September 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04313127">A Phase I Clinical Trial in 18-60 Adults</a></td>
<td>Wuhan China</td>
<td>High-dose Group, Low-dose Group, Middle-dose Group</td>
<td>March 16, 2020</td>
<td>December 20, 2022</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04260594">Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus</a></td>
<td>Unknown</td>
<td>basic treatment, Arbidol tablets + basic treatment</td>
<td>February 7, 2020</td>
<td>December 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04257656">Severe 2019-nCoV Remdesivir RCT</a></td>
<td>Beijing China</td>
<td>Remdesivir group, Control group</td>
<td>February 6, 2020</td>
<td>May 1, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04331106">Survey of the Anxiety Associated With the SARS-CoV-2 Pandemic</a></td>
<td>Berlin Germany</td>
<td>Population in Germany</td>
<td>March 27, 2020</td>
<td>September 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04291729">Evaluation of Ganovo ï¼ˆDanoprevir ï¼‰ Combined With Ritonavir in the Treatment of Novel Coronavirus Infection</a></td>
<td>Nanchang China</td>
<td>Ganovo+ritonavir with or without interferon nebulization</td>
<td>February 17, 2020</td>
<td>March 19, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04275245">Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia</a></td>
<td>Xi&rsquo;an China</td>
<td>Meplazumab</td>
<td>February 3, 2020</td>
<td>December 31, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04281693">A New Screening Strategy for 2019 Novel Coronavirus Infection</a></td>
<td>Beijing China</td>
<td>Screening participants</td>
<td>February 2020</td>
<td>March 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04315480">Tocilizumab for SARS-CoV2 Severe Pneumonitis</a></td>
<td>Ancona Italy</td>
<td>tocilizumab</td>
<td>March 2020</td>
<td>May 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04252274">Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV</a></td>
<td>Shanghai China</td>
<td>Darunavir, Cobicistat and conventional treatments</td>
<td>January 30, 2020</td>
<td>December 31, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04261517">Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV )</a></td>
<td>Shanghai China</td>
<td>Hydroxychloroquine and conventional treatments</td>
<td>February 6, 2020</td>
<td>February 25, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03331445">Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections</a></td>
<td>Vancouver Canada</td>
<td>160 ppm Nitric Oxide</td>
<td>October 24, 2017</td>
<td>March 31, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04298060">DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)</a></td>
<td>Shanghai China</td>
<td>DAS181 group, Cohort 1, Stage 2, Placebo, Cohort 1, Stage 2, DAS181 HD group Cohort 1, Stage 1, DAS181 SD group Cohort 1, Stage 1, DAS181 group, Cohort 2, Stage1 and 2, Placebo, Cohort 1, Stage 1</td>
<td>April 2020</td>
<td>September 2022</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04260308">A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia</a></td>
<td>Wuhan China</td>
<td>Unknown</td>
<td>February 3, 2020</td>
<td>April 20, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04320056">Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During Pneumonia</a></td>
<td>Unknown</td>
<td>Intervention group, Control group</td>
<td>April 6, 2020</td>
<td>October 31, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04061382">Sero-epidemiological Survey of England in 2019/2020</a></td>
<td>Oxford United Kingdom</td>
<td>Randomised selection of poplulation</td>
<td>October 15, 2019</td>
<td>November 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04273646">Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia</a></td>
<td>Wuhan China</td>
<td>UC-MSCs Treatment Group, Conventional Control Group</td>
<td>February 16, 2020</td>
<td>February 15, 2022</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04333849">Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49</a></td>
<td>Angers France</td>
<td>Unknown</td>
<td>March 27, 2020</td>
<td>September 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02735707">Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</a></td>
<td>Brisbane Australia, Barcelona Spain, Ã“zd Hungary, Frankfurt Germany, CÃ³rdoba Spain, Coventry United Kingdom, Durham United Kingdom, Rotorua New Zealand, Stockton-on-Tees United Kingdom, Toowoomba Australia, Amersfoort Netherlands, Hannover Germany, Utrecht Netherlands, Nijmegen Netherlands, Leipzig Germany, Tauranga New Zealand, Brugge Belgium, Perth Australia, Geelong Australia, Birtinya Australia, Cologne Germany, TÃ¼bingen Germany, Galway Ireland, Wellington New Zealand, Basingstoke United Kingdom, Poole United Kingdom, Gent Belgium, NyÃ­regyhÃ¡za Hungary, Edegem Belgium, Lisboa Portugal, Northampton United Kingdom, Nottingham United Kingdom, PoÅ¾ega Croatia, Berlin Germany, Leeds United Kingdom, Sydney Australia, Sidney Australia, Hamilton Canada, Groningen Netherlands, Den Bosch Netherlands, Jena Germany, Hamilton New Zealand, Toronto Canada, York United Kingdom, Bendigo Australia, Bristol United Kingdom, Truro United Kingdom, Bucharest Romania, Adelaide Australia, Christchurch New Zealand, Middlesbrough United Kingdom, Abrantes Portugal, Milton Keynes United Kingdom, Tunbridge Wells United Kingdom, Hamburg Germany, Zagreb Croatia, WÃ¼rzburg Germany, Portsmouth United Kingdom, Charleroi Belgium, Reading United Kingdom, Melbourne Australia, Maidstone United Kingdom, Dublin Ireland, Auckland New Zealand, Darwin Australia, Sherbrooke Canada, VeszprÃ©m Hungary, Darlington United Kingdom, Whangarei New Zealand, Leiden Netherlands</td>
<td>Corticosteroid Domain: shock dependant Hydrocortisone, Antibiotic Domain: Ceftriaxone + Macrolide, Hydroxychloroquine for COVID-19, Antibiotic Domain: Ceftaroline + Macrolide, Hydroxychloroquine + lopinavir/ritonavir for COVID-19, 10-day course of oseltamivir, Antibiotic Domain: Amoxicillin-clavulanate + Macrolide, Macrolide Duration Domain: Standard course macrolide, Interferon-Î²1a for COVID-19, Lopinavir/ritonavir for COVID-19, Corticosteroid Domain: fixed-duration Hydrocortisone, Five-day course of Oseltamivir, Macrolide Duration Domain: Extended course macrolide, Anakinra (interleukin-1 receptor antagonist) for COVID-19, Antibiotic Domain: Piperacillin-tazobactam + Macrolide, Antibiotic Domain: Moxifloxacin or Levofloxacin</td>
<td>April 11, 2016</td>
<td>June 2022</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04320862">Pandemic Response Network</a></td>
<td>Durham United States</td>
<td>Unknown</td>
<td>March 31, 2020</td>
<td>December 31, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04280224">NK Cells Treatment for Novel Coronavirus Pneumonia</a></td>
<td>Xinxiang China</td>
<td>NK Cells Treatment Group</td>
<td>February 20, 2020</td>
<td>December 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04261907">Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection</a></td>
<td>Unknown</td>
<td>ASC09/ritonavir group, lopinavir/ritonavir group</td>
<td>February 7, 2020</td>
<td>June 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04333589">A Prospective Study on Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive</a></td>
<td>Wenzhou China, Wuhan China, Fuyang China, Ezhou China</td>
<td>Favipiravir group</td>
<td>April 1, 2020</td>
<td>September 15, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04310228">Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019</a></td>
<td>Wuhan China, Beijing China, Hefei China</td>
<td>Favipiravir Combined With Tocilizumab group, Favipiravir group, Tocilizumab group</td>
<td>March 8, 2020</td>
<td>May 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04302519">Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells</a></td>
<td>Unknown</td>
<td>Pulp mesenchymal stem cells</td>
<td>March 5, 2020</td>
<td>July 30, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04275388">Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia</a></td>
<td>Unknown</td>
<td>Xiyanping injection +other drugs, other drugs</td>
<td>February 14, 2020</td>
<td>December 14, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04333875">Morbidity and Mortality Due to Deferral of Aortic Valve Replacement in Patients With Severe Aortic Stenosis</a></td>
<td>Bern Switzerland</td>
<td>TAVR/SAVR</td>
<td>March 20, 2020</td>
<td>December 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04283838">Humanistic Care in Healthcare Workers in Coronavirus Disease 2019</a></td>
<td>Unknown</td>
<td>Humanistic care</td>
<td>February 22, 2020</td>
<td>May 15, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04244591">Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory Failure</a></td>
<td>Beijing China</td>
<td>standard care, standard care + methylprednisolone therapy</td>
<td>January 26, 2020</td>
<td>December 25, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04226157">Home Blood Pressure Study for Recent Stroke Survivors With High Blood Pressure <em>Due to COVID-19 Outbreak in United States the Investigators Have Paused All In-person Enrollment and Will Re-evaluate on May 1st</em></a></td>
<td>Washington United States</td>
<td>Usual Care, Home Blood Pressure Self Management</td>
<td>February 21, 2019</td>
<td>March 31, 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04322786">The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?</a></td>
<td>Unknown</td>
<td>ACEI user</td>
<td>January 1, 1998</td>
<td>March 31, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04329897">Acceptance and Commitment Therapy Delivered by Automated Software Messaging</a></td>
<td>Unknown</td>
<td>Software Messaging</td>
<td>March 31, 2020</td>
<td>June 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04293887">Efficacy and Safety of IFN-Î±2Î² in the Treatment of Novel Coronavirus Patients</a></td>
<td>Unknown</td>
<td>Standard therapy + interferon therapy</td>
<td>March 1, 2020</td>
<td>June 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03680274">Lessening Organ Dysfunction With VITamin C</a></td>
<td>Sherbrooke Canada</td>
<td>Control, Vitamin C</td>
<td>November 8, 2018</td>
<td>December 31, 2022</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04276987">A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia</a></td>
<td>Unknown</td>
<td>MSCs-derived Exosomes Treatment Group</td>
<td>February 15, 2020</td>
<td>July 31, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04276688">Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment</a></td>
<td>Hong Kong Hong Kong</td>
<td>Control group, Study group</td>
<td>February 10, 2020</td>
<td>July 31, 2022</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04283825">Humanistic Care in Patients With Coronavirus Disease 2019</a></td>
<td>Unknown</td>
<td>Humanistic care</td>
<td>February 22, 2020</td>
<td>May 15, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04317365">Awareness Between Pregnant Women Regarding Corona</a></td>
<td>Giza Egypt</td>
<td>Unknown</td>
<td>March 24, 2020</td>
<td>May 2, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04158648">A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors</a></td>
<td>WrocÅ‚aw Poland, Cardiff United Kingdom, Bonn Germany, London United Kingdom, Detroit United States, St. John&rsquo;s Canada, Indianapolis United States, Seattle United States, Decatur United States, Washington United States, Leuven Belgium, Le Kremlin Bicetre France, Bron France, MÃ¼nchen Germany, Johannesburg South Africa, Paris France, Madrid Spain, Sevilla Spain, Edmonton Canada, Amsterdam Netherlands, Warsaw Poland, Ann Arbor United States, Los Angeles United States, Bruxelles Belgium</td>
<td>Emicizumab</td>
<td>February 10, 2020</td>
<td>July 19, 2022</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04330352">Mindfulness-based &ldquo;STOP (Stop, Take a Breath, Observe, Proceed) Touching Your Face&rdquo; Intervention</a></td>
<td>Unknown</td>
<td>Mindfulness-based &ldquo;STOP touching your face&rdquo; intervention</td>
<td>March 30, 2020</td>
<td>April 30, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04299711">Mental Health and Its Correlates Among Chinese Adolescents Exposed to the Novel Coronavirus Disease 2019</a></td>
<td>Unknown</td>
<td>6-month follow-up, 18-month follow-up, Baseline, 12-month follow-up</td>
<td>October 15, 2020</td>
<td>March 15, 2022</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04274621">The Application Value of Non-contact Infrared Thermometers in Temperature Screening in the General Population</a></td>
<td>Ningbo China</td>
<td>Unknown</td>
<td>February 14, 2020</td>
<td>February 20, 2020</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04262921">Clinical Characterisation Protocol for Severe Emerging Infections</a></td>
<td>Paris France, Bordeaux France</td>
<td>Unknown</td>
<td>February 7, 2020</td>
<td>August 7, 2023</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03710746">Project Health: Enhancing Effectiveness of a Dissonance-Based Obesity Prevention Program</a></td>
<td>Eugene United States, Philadelphia United States</td>
<td>Female Group, Food Response Training, Male Group, Food Response Training, Male Group, Generic Response Training, Mixed Group, Generic Response Training, Mixed Group, Food Response Training, Female Group, Generic Response Training</td>
<td>October 8, 2018</td>
<td>July 31, 2023</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03620409">Identification of Cardiovascular and Molecular Prognostic Factors for the Mid- and Long-term Outcome of Sepsis</a></td>
<td>Jena Germany</td>
<td>Unknown</td>
<td>May 9, 2018</td>
<td>June 2021</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03184662">Efficacy of a High-intensity Physical Activity Program on Renal Function in High Risk Patients With Type 2 Diabetes</a></td>
<td>Toulouse France, Paris France, BesanÃ§on France, Lille France, Tours France, Clermont Ferrand France, Lyon France, Poitiers France, LiÃ¨ge Belgium, Caen France, Chartres France, Bordeaux France, Montpellier France, Nancy France, Dijon France, Nice France, Strasbourg France, Corbeil-Essonnes France</td>
<td>Control group, HIPA group</td>
<td>February 12, 2018</td>
<td>July 31, 2023</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT04326309">Audio Data Collection for Identification and Classification of Coughing</a></td>
<td>Bronx United States</td>
<td>Unknown</td>
<td>March 25, 2020</td>
<td>September 25, 2022</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03261050">Target Engagement of a Novel Dissonance-Based Treatment for DSM-5 Eating Disorders</a></td>
<td>Eugene United States, Austin United States, Stanford United States</td>
<td>R33 (Phase 2), R61 (Phase 1)</td>
<td>July 10, 2017</td>
<td>June 2022</td>
</tr>
</tbody>
</table>

</div>
  
  <br><br>
  <a href='https://ko-fi.com/F1F81KK4Q' target='_blank'><img height='36' style='border:0px;height:36px;' src='https://cdn.ko-fi.com/cdn/kofi1.png?v=2' border='0' alt='Buy Me a Coffee at ko-fi.com' /></a>
  
<footer class='entry-footer'>
  <div class='container sep-before'>
  </div>
</footer>


</article>


<nav class='entry-nav'>
  <div class='container'><div class='next-entry sep-before'>
      <a href='/about/'>
        <span class='screen-reader-text'>Next post: </span>About<span aria-hidden='true'>Next <svg class='icon' viewbox='0 0 24 24' stroke-linecap='round' stroke-linejoin='round' stroke-width='2' aria-hidden='true'>
  
  <line x1="4" y1="12" x2="20" y2="12"/>
  <polyline points="14 6 20 12 14 18"/>
  
</svg>
</span>
      </a>
    </div></div>
</nav>




      </main>

      <footer id='footer' class='footer'>
        <div class='container sep-before'><section class='widget widget-social_menu sep-after'><nav aria-label='Social Menu'>
    <ul><li>
        <a href='https://twitter.com/paperscovid' target='_blank' rel='noopener'>
          <span class='screen-reader-text'>Open Twitter account in new tab</span><svg class='icon' viewbox='0 0 24 24' stroke-linecap='round' stroke-linejoin='round' stroke-width='2' aria-hidden='true'>
  
  <path d="M23 3a10.9 10.9 0 0 1-3.14 1.53 4.48 4.48 0 0 0-7.86 3v1A10.66 10.66 0 0 1 3 4s-4 9 5 13a11.64 11.64 0 0 1-7 2c9 5 20 0 20-11.5a4.5 4.5 0 0 0-.08-.83A7.72 7.72 0 0 0 23 3z"/>
  
</svg>
</a>
      </li><li>
        <a href='mailto:paperscovid@gmail.com' target='_blank' rel='noopener'>
          <span class='screen-reader-text'>Contact via Email</span><svg class='icon' viewbox='0 0 24 24' stroke-linecap='round' stroke-linejoin='round' stroke-width='2' aria-hidden='true'>
  
  <path d="M4 4h16c1.1 0 2 .9 2 2v12c0 1.1-.9 2-2 2H4c-1.1 0-2-.9-2-2V6c0-1.1.9-2 2-2z"/>
  <polyline points="22,6 12,13 2,6"/>
  
</svg>
</a>
      </li></ul>
  </nav>
</section><div class='copyright'>
  <p> &copy; 2020 Covid Papers </p>
</div>

        </div>
      </footer>

    </div>
  </div><script>window.__assets_js_src="/assets/js/"</script>

<script src='/assets/js/main.c3bcf2df.js'></script><script src='/js/custom.js'></script>

</body>

</html>


<script type="text/javascript" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-5e86803189bd8f96"></script>
